Charles Schwab’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-246,086
| Closed | -$2.45M | – | 3502 |
|
|
2025
Q2 | $2.45M | Buy |
246,086
+12,525
| +5% | +$101K | ﹤0.01% | 2606 |
|
|
2025
Q1 | $1.39M | Buy |
233,561
+34,365
| +17% | +$252K | ﹤0.01% | 2730 |
|
|
2024
Q4 | $1.53M | Sell |
199,196
-22,939
| -10% | -$197K | ﹤0.01% | 2757 |
|
|
2024
Q3 | $2.27M | Buy |
222,135
+8,397
| +4% | +$128K | ﹤0.01% | 2666 |
|
|
2024
Q2 | $3.17M | Buy |
213,738
+7,873
| +4% | +$113K | ﹤0.01% | 2539 |
|
|
2024
Q1 | $2.81M | Buy |
205,865
+4,315
| +2% | +$47K | ﹤0.01% | 2494 |
|
|
2023
Q4 | $2.21M | Sell |
201,550
-8,621
| -4% | -$85.5K | ﹤0.01% | 2586 |
|
|
2023
Q3 | $2.3M | Buy |
210,171
+19,258
| +10% | +$246K | ﹤0.01% | 2556 |
|
|
2023
Q2 | $2.53M | Buy |
190,913
+7,947
| +4% | +$113K | ﹤0.01% | 2481 |
|
|
2023
Q1 | $2.49M | Buy |
182,966
+477
| +0.3% | +$8.55K | ﹤0.01% | 2465 |
|
|
2022
Q4 | $3.56M | Buy |
182,489
+4,322
| +2% | +$84.5K | ﹤0.01% | 2378 |
|
|
2022
Q3 | $3.39M | Buy |
178,167
+27,288
| +18% | +$629K | ﹤0.01% | 2418 |
|
|
2022
Q2 | $3.11M | Buy |
150,879
+5,130
| +4% | +$122K | ﹤0.01% | 2397 |
|
|
2022
Q1 | $4.69M | Buy |
145,749
+3,174
| +2% | +$115K | ﹤0.01% | 2309 |
|
|
2021
Q4 | $6.64M | Buy |
142,575
+2,057
| +1% | +$68.5K | ﹤0.01% | 2211 |
|
|
2021
Q3 | $3.79M | Buy |
140,518
+43,432
| +45% | +$1.14M | ﹤0.01% | 2500 |
|
|
2021
Q2 | $2.49M | Buy |
97,086
+3,374
| +4% | +$80.4K | ﹤0.01% | 2634 |
|
|
2021
Q1 | $3.2M | Buy |
93,712
+18,961
| +25% | +$685K | ﹤0.01% | 2510 |
|
|
2020
Q4 | $2.53M | Buy |
74,751
+5,610
| +8% | +$149K | ﹤0.01% | 2531 |
|
|
2020
Q3 | $1.71M | Buy |
+69,141
| New | +$1.86M | ﹤0.01% | 2545 |
|
Other funds holding ITOS
Charles Schwab's ITOS Position: Q3 2025 in Review
Charles Schwab sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 246,086 shares — an estimated $2.45M sold.
Charles Schwab first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $6.64M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Charles Schwab reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Charles Schwab sold 246,086 iTeos Therapeutics shares in Q3 2025, an estimated $2.45M.
- Charles Schwab first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- Charles Schwab's iTeos Therapeutics position peaked at $6.64M in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.